Helicobacter pylori Research in Human Health
A special issue of Gastrointestinal Disorders (ISSN 2624-5647).
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 2533
Special Issue Editors
Interests: study of microbial survival strategies (biofilm, non-cultivable vital state), evaluation of antimicrobial, anti-biofilm and anti-virulence activities of bioactive substances of natural origin; semi-synthesis and innovative biomaterials; the research activity has concerned oral cavity microorganisms; Helicobacter pylori and microorganisms related to chronic wounds (Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans) and lung infections (Mycobacterium abscessus and other fast-growing mycobacteria)
Special Issues, Collections and Topics in MDPI journals
Interests: antimicrobial; anti-biofilm and anti-virulence activities of natural compounds alone and combined with antibiotics against multi drug-resistant strains (Helicobacter pylori, Staphylococcus spp., Pseudomonas aeruginosa, Candida albicans, Mycobacterium abscessus and other fast-growing mycobacteria)
Special Issues, Collections and Topics in MDPI journals
2. Clinical Microbiology and Virology Unit, Careggi University Hospital, 50139 Florence, Italy
Interests: antimicrobial resistance; rapid clinical microbiology; diagnostic stewardship; carbapenem-resistant Gram-negatives; oxazolidinone-resistant Gram-positives
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Helicobacter pylori is a bacterial gastroduodenal pathogen colonizing around 50% of the world population, representing the main cause of chronic gastritis, peptic ulcer disease and gastric cancer.
The IARC classified H. pylori as a type I carcinogen, recommending the treatment of its infection when the bacterium is diagnosed to prevent gastric cancer.
The development of Anti-H.pylori treatment strategies remain a challenge due its high antibiotic resistance; the WHO listed this bacterium among the pathogens for which increasing antibiotic resistance represents a serious threat for human health.
In addition, H. pylori is able to evade and manipulate the host immune system and establish chronic infection, producing biofilms and entering into a dormant state, inducing a tolerant state against antimicrobial drugs. Innovative therapies are thus needed, such as natural substances associated with drugs commonly used in therapy, which demonstrate a capability to act as antibiotic resistance breakers, probiotics, human-derived-peptides and photodynamic therapy, which are well-described in the literature.
This Special Issue will focus on the latest advances in innovative treatments for H. pylori’s eradication.
Topics of interest include, but are not limited to, the following:
- Antibiotic resistance breakers in pylori treatment;
- New strategies against pylori biofilms and dormancy state;
- New synergic natural compounds/antibiotic association in pylori treatment.
Dr. Mara Di Giulio
Dr. Silvia Di Lodovico
Dr. Alberto Antonelli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastrointestinal Disorders is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Helicobacter pylori
- biofilm and vBNC state
- innovative antimicrobial strategies
- anti-virulence action